Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.

Dolton MJ, D'Argenio DZ.

J Antimicrob Chemother. 2017 Apr 1;72(4):1129-1136. doi: 10.1093/jac/dkw553.

2.

Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.

Dolton MJ, McLachlan AJ.

Curr Opin Infect Dis. 2014 Dec;27(6):493-500. doi: 10.1097/QCO.0000000000000103. Review.

PMID:
25229352
3.

Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Dolton MJ, Br├╝ggemann RJ, Burger DM, McLachlan AJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6879-85. doi: 10.1128/AAC.03777-14. Epub 2014 Sep 8.

4.

Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.

Dolton MJ, McLachlan AJ.

Int J Antimicrob Agents. 2014 Sep;44(3):183-93. doi: 10.1016/j.ijantimicag.2014.05.019. Epub 2014 Jul 7. Review.

PMID:
25106074
5.

Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Perera V, Bies RR, Mo G, Dolton MJ, Carr VJ, McLachlan AJ, Day RO, Polasek TM, Forrest A.

Br J Clin Pharmacol. 2014 Oct;78(4):800-14. doi: 10.1111/bcp.12410.

6.

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.

Dolton MJ, Mikus G, Weiss J, Ray JE, McLachlan AJ.

J Antimicrob Chemother. 2014 Jun;69(6):1633-41. doi: 10.1093/jac/dku031. Epub 2014 Feb 18.

PMID:
24554646
7.

Pharmacometrics: an underused resource in Australian clinical research.

Perera V, Dolton MJ, McLachlan AJ, Carr VJ, Day RO.

Med J Aust. 2014 Feb 3;200(2):82-3. No abstract available.

PMID:
24484099
8.
9.

Reply to "What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?".

Dolton MJ, McLachlan AJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2906. doi: 10.1128/AAC.00592-13. No abstract available.

10.

Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.

Dolton MJ, Ray JE, McLachlan AJ.

Ther Drug Monit. 2013 Jun;35(3):414-5. doi: 10.1097/FTD.0b013e318285e87c. No abstract available.

PMID:
23670484
11.

Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides.

Dolton MJ, Roufogalis BD, McLachlan AJ.

Clin Pharmacol Ther. 2012 Nov;92(5):622-30. doi: 10.1038/clpt.2012.159. Epub 2012 Oct 3. Review.

PMID:
23033114
12.

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ.

Antimicrob Agents Chemother. 2012 Nov;56(11):5503-10. doi: 10.1128/AAC.00802-12. Epub 2012 Aug 13.

13.

Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.

Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4793-9. doi: 10.1128/AAC.00626-12. Epub 2012 Jul 2.

14.

Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Dolton MJ, Ray JE, Marriott D, McLachlan AJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):2806-13. doi: 10.1128/AAC.05900-11. Epub 2012 Mar 5. Review.

15.

Clinical importance of the CYP2C19*17 variant allele for voriconazole.

Dolton MJ, McLachlan AJ.

Br J Clin Pharmacol. 2011 Jan;71(1):137-8. doi: 10.1111/j.1365-2125.2010.03801.x. No abstract available.

Supplemental Content

Loading ...
Support Center